Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 5/20 | 0.42 |
| ▸ | ALPI | P09923 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872184 | 0.89 | ADA (0.46) | ADAALPIALDH1A1SMN1; SMN2ADORA2A | |
| SCHEMBL15261376 | 0.86 | ADA (0.47) | ADAALPIALDH1A1SMN1; SMN2ADORA2A | |
| SCHEMBL15261779 | 0.86 | ADA (0.44) | ADAALPIALDH1A1SMN1; SMN2ADORA2A | |
| SCHEMBL881892 | 0.84 | ADA (0.47) | ADAALPIALDH1A1SMN1; SMN2ADORA2A | |
| SCHEMBL872452 | 0.83 | ADA (0.42) | ADAALPIALDH1A1SMN1; SMN2ADORA2A | |
| SCHEMBL15261839 | 0.83 | ADA (0.42) | ADAALPIALDH1A1SMN1; SMN2ADORA2A | |
| SCHEMBL8285072 | 0.76 | ADA (0.58) | ADAALPIALDH1A1SMN1; SMN2ADORA2A | |
| SCHEMBL872480 | 0.73 | KDM4E (0.45) | ADAALDH1A1SMN1; SMN2ADORA2ARAB9A | |
| SCHEMBL27914295 | 0.73 | ADORA2A (0.35) | ADORA2AHDAC1 | |
| SCHEMBL881444 | 0.71 | KDM5A (0.39) | ALDH1A1SMN1; SMN2ADORA2AHDAC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619211-B1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| EP-2619211-B1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| WO-2012038980-A2 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | ADA 65/4885ALPI 680/4885ALDH1A1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.